咪喹莫特对伴有高危型HPV感染的宫颈尖锐湿疣疗效及HPV DNA含量的影响

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (2705 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effect of imiquimod on cervical condyloma acuminate accompanied with high-risk HPV infections, and the content of HPV-DNA. Methods: One hundred and twenty female patients with cervical condyloma acuminate and high-risk HPV infections were randomly divided into treatment goup and control group, and each group was administered either 5% imiquimod local treatment or high frequency cauterization. The dropping of verrucous, wound healing, recurrence and adverse reactions between the two groups were analyzed. HPV gene sequencing was conducted, and the viral load of HPV-DNA was compared before and after treatment between the two groups. Results: At 4, 8, 12 weeks after treatment, the clearance rate of verrucous were 25.0% (13/52), 65.4% (34/52), and 84.6% (44/52) in the treatment group, respectively. Meanwhile, the clearance rate of verrucous were 30.9% (17/55), 70.9% (39/55), and 74.5% (41/55), respectively. There were no significant differences between two groups (P>0.05). The recurrence rate was 10.2% (5/52) in the treatment group, which was significantly lower compared to the control group (P<0.05). HPV gene sequencing showed that HPV type 16 was most common in cervical condyloma acuminate in our hospital, followed by type 52 and 58. After 3 and 6 months follow-up, HPV negative conversion rate in treatment group was 28.2% (15/52) and 59.6% (31/52), and statistically significant over that of 12.7% (7/55) and 27.3% (15/55) in the control group. Besides, the viral load of HPV-DNA in the treatment group was significantly lower compared to the control group (P<0.05). Conclusion: 5% imiquimod can remove verrucous of cervical condyloma acuminate and additionally prevent recurrence and cure high-risk HPV. This result shows that 5% imiquimod is effective in the treatment and the prevention of relapse cervical condyloma acuminate.

Key words： imiquimod cervical condyloma acuminate human papillomavirus

Received: 15 April 2016

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Jianqin
	HU Yan
	ZHOU Qiangyong
	XU Yunsheng

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2017/V47/I1/29

[1] 张学军. 皮肤性病学[M]. 6版, 北京: 人民卫生出版社, 2004: 220-221.
[2] CDC. Sexually transmitted diseases treatment guidelines[R]. MMWR, 2006, 55: RR-11.
[3] 徐文严. 性传播疾病预防与治疗[M]. 上海: 第二军医大学出版社, 2001: 3-5.
[4] TRAN H, MORENO G, SHRMACK S. Imiquimod as a dermatological therapy[J]. Expert Opin Pharmacother, 2004, 5(2): 427-438.
[5] SAUDER D N. Immunomodulatory and pharmacologic properties of imiquimod[J]. J Am Acad Dermatol, 2000, 43(1): 6- 11.
[6] KONO T, KONDO S, PASTORE S, et al. Effects of a novel topical immunomodulator, imiquimod, onkeratinocyte cytokine gene expression[J]. Lymphokine Cytokine Res, 1994,13(2): 71-76.
[7] TYRING S K, ARANY I, STANLEY M A, et al. Arandomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod[J]. J Infect Dis, 1998, 178(2): 551-555.
[8] TYRING S K, ARANY I, STANLEY M A, et al. Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts[J]. Prim Care Update Ob Gyns, 1998, 5(4): 151-152.
[9] 陶苏江, 顾军, 赵广, 等. 5%咪喹莫特乳膏治疗尖锐湿疣的临床研究[J]. 中国皮肤性病学杂志, 2006, 20(3): 147-148.
[10] EDWARDS L, FERENCZY A, ERON L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV study group. Human Paplilomavirus[J]. Arch Dermatol, 1998, 134 (1): 25-30.
[11] BEUTNER K R, SPRUANCE S L, HOUGHAM A J, et al. Treatment of genital warts with an immune-response modifier (imiquimod)[J]. J Am Acad Dermatol, 1998, 38 (2Pt 1):230-239.
[12] VILATA J J, SIERRA X. Efficacy of imiquimod 5% cream in treating genital and perianal warts[J]. Ann Dermatol Venereol, 2002, 129: S322.
[13] DIAZ-ARRASTIA C, ARANY I, ROBAZETTI S C, et al. Clinical and molecular responses in high- grade intraepithelial neoplasia treated with topical imiquimod 5%[J]. Clin Cancer Res, 2001, 7(10): 3031-3033.
[14] 钱伊弘, 王学民. 循证医学方法评价干扰素治疗尖锐湿疣[J]. 临床皮肤科杂志, 2003, 22(3): 139-140.
[15] SAUDER D N, SKINNER R B, FOX T L, et al. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations[J].Sex Transm Dis, 2003, 30(2): 124-128.